BeiGene proposes name change, redomiciling to Switzerland in 2025

BeiGene (HKEX:6160) has announced key proposals for its upcoming 2025 Annual General Meeting, signaling a strategic shift towards global integration and brand evolution. The company plans to seek shareholder approval for a name change to BeOne Medicines Ltd. and a redomiciling to Switzerland. This reflects BeiGene's expanding global footprint and a refocused mission to eliminate cancer through global partnerships. Key design attributes of BeOne’s new logo include representations of disease freedom, unified patient care, oncology commitment, and an “always on” approach to innovative medicines.